You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

51 search results for: itch

<b>Itch</b> in AD, PN and CSU: Role of Type 2 Inflammation

expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

27 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

The Path to Nodules: Type 2 Inflammation at the Core of Chronic <b>Itch</b> and Fibrosis in Prurigo Nodularis

expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min

Type 2 Inflammation

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

expert video

Mast Cells and the Neuroimmune Axis in CSU

10 min

Dermatology

A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.

Neuroiflammation and Neurogenic <b>Itch</b> in Prurigo Nodularis

expert video

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

2 min

Dermatology

Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.

Emerging Understanding of Chronic <b>Itch</b>y Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

5 min

Dermatology

An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.

expert video

Neuroimmune Axis in Atopic Dermatitis

8 min

Dermatology

A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.

expert video

Neuroimmune Axis and Neuroinflammation in PN

11 min

Dermatology

A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.

Dysbiosis, Skin Infections, and <b>Itch</b>

expert video

Dysbiosis, Skin Infections, and Itch

3 min

Dermatology

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.

Role of Type 2 Inflammation in Skin Barrier Disruption and <b>Itch</b>

expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

4 min

Dermatology

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD

Contribution of Type 2 Cytokines to Inflammation and <b>Itch</b> in AD, PN, and CSU

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

videoanimation

The Pathophysiology of Prurigo Nodularis

5 min

Dermatology

An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

Under the <b>Itch</b>y Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Hong KongChange country/region